Business
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.","length":465,"tagName":"p"},{"type":"image","alt":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4B69KZz1nJO8NbFw7Kh3Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/602982/ITUS_Corporation_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar will deliver an investor presentation and corporate update. The presentation will include a review of recent clinical milestones across the Company's oncology pipeline, including:","length":286,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Encouraging survival observations and regulatory approval for substantial dose escalation in the Company's ongoing Phase 1 ovarian cancer CAR-T trial; and","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Final Phase 1 data from the breast cancer vaccine program, which met primary endpoints and demonstrated favorable tolerability and protocol-defined immune responses in the majority of participants.","length":197,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":355,"olType":false},{"type":"text","content":"The presentation w...